Rovira, Àlex http://orcid.org/0000-0002-2132-6750
Doniselli, Fabio M. http://orcid.org/0000-0002-2272-7855
Auger, Cristina http://orcid.org/0000-0001-9846-4767
Haider, Lukas http://orcid.org/0000-0002-1556-1770
Hodel, Jerome http://orcid.org/0000-0002-9029-6890
Severino, Mariasavina http://orcid.org/0000-0003-4730-5322
Wattjes, Mike P. http://orcid.org/0000-0001-9298-2897
van der Molen, Aart J. http://orcid.org/0000-0002-2376-9424
Jasperse, Bas http://orcid.org/0000-0003-1577-8299
Mallio, Carlo A. http://orcid.org/0000-0002-0149-0801
Yousry, Tarek http://orcid.org/0000-0003-3295-0628
Quattrocchi, Carlo C. http://orcid.org/0000-0001-6823-7707
,
Article History
Received: 24 April 2023
Revised: 6 July 2023
Accepted: 12 July 2023
First Online: 2 September 2023
Declarations
:
: The scientific guarantor of this publication is Dr. Rovira.
: (a) Àlex Rovira serves/ed on scientific advisory boards for Novartis, Sanofi-Genzyme, Icometrix, SyntheticMR, Bayer Healthcare, Biogen, and OLEA Medical, and has received speaker honoraria from Bayer Healthcare, Sanofi-Genzyme, Bracco Imaging, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche, and Biogen.(b) Fabio Doniselli, Cristina Auger, Jérôme Hodel, Mariasavina Severino, Bas Jasperse, Tarek Yousry, and Carlo Augusto Mallio do not have any conflict of interest to disclosure.(c) Lukas Haider was supported by an ESNR (European Society of Neuro-Radiology) Research Fellowship and the ECTRIMS-MAGNIMS Research Fellowship and received funding from the Austrian MS Society.(d) M. P. Wattjes received speaker or consultancy honoraria from Alexion, Bayer Healthcare, Biogen, Biologix, Celgene, Genilac, Imcyse, IXICO, Icometrix, Medison, Merck-Serono, Novartis, Roche, and Sanofi-Genzyme; publication royalties from Springer and Elsevier.(e) A. J. van der Molen receives consultancy fees from Guerbet as a member of the Expert Group for Gadopiclenol in The Netherlands. He is a member of the ESUR-CMSC whose 2-yearly meetings have received support from Bayer Healthcare, Bracco Imaging, GE HealthCare, and Guerbet.(f) Carlo Cosimo Quattrocchi has signed speaker contracts with Bayer Healthcare, Bracco Imaging, and Guerbet. He is co-chair of the ESMRMB-GREC Working Group whose yearly meetings have received unconditional support from Bayer Healthcare, Bracco Imaging, GE HealthCare, and Guerbet. He is a member of the ESUR-CMSC whose 2-yearly meetings have received support from Bayer Healthcare, Bracco Imaging, GE HealthCare, and Guerbet.
: The authors have significant statistical expertise. No complex statistical methods were necessary for this paper.
: Written informed consent was not required for this study because this is a review article.
: Institutional Review Board approval was not required because this is a review article.
: No study subject or cohort overlap reported.
: • Multicentre study